HQY Price Prediction Next Week
HQY Stock Price Prediction and Recommendation
Technical Analysis:
- Current Price: $100.07 (as of 2025-03-10).
- RSI: Oversold at 24.32 (RSI_6), indicating potential for a bounce.
- MACD: Bearish crossover with a negative value, but the histogram shows early signs of divergence.
- Stochastic Oscillator: %K (17.68) is below %D (21.56), suggesting continued bearish momentum.
- Fibonacci Levels: Key support at 100.40 (S1) and 97.38 (S2), with resistance at 110.18 (R1).
News and Fundamental Analysis:
- Analyst Target: HQY has surpassed the average 12-month target price of $113.33, trading at $114.51, prompting potential target adjustments or downgrades.
- Company Growth: Reported strong HSA and asset growth, with estimates of 9.8 million HSAs and $31 billion in assets, indicating solid fundamentals.
- Upcoming Event: Presentation at the J.P. Morgan Healthcare Conference, which could bring positive news and investor interest.
Price Prediction and Recommendation:
- Target Price: $97.38 (S2 support level).
- Recommendation: Sell HQY in the next trading week, as technical indicators suggest continued downward pressure despite positive fundamentals.
HQY Similar Chart Price Prediction
The price of HQY is predicted to go up -12.24%, based on the high correlation periods with UGP. The similarity of these two price pattern on the periods is 96.11%.
HQY
UGP
Down: -12.24%Similarity: 96.11%
HQY Revenue Forecast
HQY EPS Forecast
HQY FAQs
What is HQY revenue forecast for next quarter？
What is HQY eps forecast for next quarter？
HQY Analyst's Forecast
Stan Berenshteyn
Wells Fargo
Buy
2025-02-26
Price Target
$110 → $125
Upside
+18.36%
Wells Fargo analyst Stan Berenshteyn raised the firm's price target on HealthEquity to $125 from $110 and keeps an Overweight rating on the shares as the firm sees factor favorable rate setup. There are several bills in play that could drive TAM upside for HealthEquity, including a bill that could push HSAs into the Medicare/Medicaid space, HSA Modernization that may increase HSA contribution limits, a bill that could decouple HSAs from HDHPs, and the HOPE act, which Wells previously estimated represents 4-times today's HSA market and for HealthEquity a cross-sale opportunity worth about $1.5B.
Constantine Davides
JMP Securities
Buy
2024-12-10
Price Target
$105 → $107
Upside
+12.17%
Steven Valiquette
Mizuho
Buy
2024-12-04
Price Target
$126
Upside
+22.33%
